Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease

Each participant of the study will have their data collected from the date of confirmed diagnosis of PD to the date of enrollment in the registry, post consent. Data will be collected from the participant's clinical records as well as from the participant directly. Data will be collected through Pulse Infoframe's technology platform.

Primary outcomes

• Number of Participants Receiving Each Treatment Type for PD [Up to 12 months]

Secondary outcomes

• Change from Baseline in Peyronie's Disease Questionnaire (PDQ) Score [Up to 12 months]
• Change from Baseline in International Index of Erectile Function (IIEF) Score [Up to 12 months]
• Change from Baseline in Patient Health Questionnaire-9 (PHQ-9) Score [Up to 12 months]
• Change from Baseline in Beck Anxiety Inventory (BAI) Scale Score [Up to 12 months]
• Participant Satisfaction Questionnaire [Up to 12 months]
• Number of Participants Receiving Post-Procedural Care by the Treating Physician [Up to 12 months]

Sex: Male, ages: 18 Years to any

Key Inclusion Criteria:

* Any adult with a confirmed clinical diagnosis of PD.
* Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment.
* Willing to participate in the registry (including completion of ePROs) and complete the informed consent form.
* Having received PD treatment within 2 weeks before enrollment, at enrollment or any time after the date of enrollment. After a confirmed diagnosis of PD, not having received PD treatment.
* Able to participate in English based registry.

Key Exclusion criteria:

* Not having a clinical diagnosis of PD.
* Age less than 18 years.
* Do not provide informed consent.

• Medical Information, Study director, Endo USA Inc., a Keenova Therapeutics Company